Evidence map›Paper›PMID 25415317›Full record

ArticlePloS one2014

Role of focal adhesion tyrosine kinases in GPVI-dependent platelet activation and reactive oxygen species formation.

Naadiya Carrim, Tony G Walsh, Alessandra Consonni, Mauro Torti, Michael C Berndt, Pat Metharom

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Redox Control in Platelet Activity and Therapy.Antioxidants (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. An optimized herbal medicine containingJournal of traditional and complementary medicine · 2023
    Article
  6. Article
  7. Review
  8. PI3K Isoform Signalling in Platelets.Current topics in microbiology and immunology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Naadiya CarrimDepartment of Experimental Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Tony G WalshDepartment of Experimental Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
Alessandra ConsonniLaboratories of Biochemistry, Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Mauro TortiLaboratories of Biochemistry, Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Michael C BerndtDepartment of Experimental Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, Australia.
Pat MetharomDepartment of Experimental Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland; Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, Australia.
Royal College of Surgeons in Ireland · IEUniversity of Pavia · ITCurtin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have previously shown the presence of a TRAF4/p47phox/Hic5/Pyk2 complex associated with the platelet collagen receptor, GPVI, consistent with a potential role of this complex in GPVI-dependent ROS formation. In other cell systems, NOX-dependent ROS formation is facilitated by Pyk2, which along with its closely related homologue FAK are known to be activated and phosphorylated downstream of ligand binding to GPVI.

aimsTo evaluate the relative roles of Pyk2 and FAK in GPVI-dependent ROS formation and to determine their location within the GPVI signaling pathway. METHODS AND

resultsHuman and mouse washed platelets (from WT or Pyk2 KO mice) were pre-treated with pharmacological inhibitors targeting FAK or Pyk2 (PF-228 and Tyrphostin A9, respectively) and stimulated with the GPVI-specific agonist, CRP. FAK, but not Pyk2, was found to be essential for GPVI-dependent ROS production and aggregation. Subsequent human platelet studies with PF-228 confirmed FAK is essential for GPVI-mediated phosphatidylserine exposure, α-granule secretion (P-selectin (CD62P) surface expression) and integrin αIIbβ3 activation. To determine the precise location of FAK within the GPVI pathway, we analyzed the effect of PF-228 inhibition in CRP-stimulated platelets in conjunction with immunoprecipitation and pulldown analysis to show that FAK is downstream of Lyn, Spleen tyrosine kinase (Syk), PI3-K and Bruton's tyrosine kinase (Btk) and upstream of Rac1, PLCγ2, Ca2+ release, PKC, Hic-5, NOX1 and αIIbβ3 activation.

conclusionOverall, these data suggest a novel role for FAK in GPVI-dependent ROS formation and platelet activation and elucidate a proximal signaling role for FAK within the GPVI pathway.

Indexed as

AnimalsBlood PlateletsCytoskeletal ProteinsDNA-Binding ProteinsFemaleFocal Adhesion Kinase 1Focal Adhesion Kinase 2HumansIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMaleMiceMice, KnockoutNADPH OxidasesPlatelet ActivationPlatelet Membrane GlycoproteinsCytoskeletal ProteinsDNA-Binding ProteinsFocal Adhesion Kinase 1Focal Adhesion Kinase 2Intracellular Signaling Peptides and ProteinsLIM Domain ProteinsNADPH Oxidasesneutrophil cytosolic factor 1Platelet Membrane Glycoproteinsplatelet membrane glycoprotein VIPTK2B protein, humanPtk2b protein, mousePTK2 protein, humanPtk2 protein, mouseReactive Oxygen SpeciesTGFB1I1 protein, humanTgfb1i1 protein, mouseTNF Receptor-Associated Factor 4TRAF4 protein, humanTraf4 protein, mouse

Identifiers

PMID25415317
PMCPMC4240642
OpenAlexW1965314978

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.